Drugs.com - Clinical Trials

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

South San Francisco, CA -- December 18, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s...

Feb 9, 2025 - 21:44
 0
Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
South San Francisco, CA -- December 18, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s...
Read More

Tags:

Previous Article

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in...

Next Article

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiov...

Related Posts

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Provides Update on BEACON-IPF, a Ph...

Feb 10, 2025  0

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience Receives FDA Fast Track Designation ...

Feb 9, 2025  0

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025  0